Oxthera AB is a research institute based in Stockholm that specializes in the treatment of primary hyperoxaluria, a rare genetic disorder that can lead to kidney damage. The organization conducts Phase 3 clinical studies to evaluate the efficacy and safety of its therapeutic solutions. One of its notable developments is Oxabact, which has recently received a patent in the United States, marking a significant milestone in its research efforts.
The primary goal of Oxthera AB is to maintain kidney function in patients suffering from primary hyperoxaluria. The institute is dedicated to innovative research and development, focusing on improving patient outcomes through scientific advancements in the field of rare diseases. Oxthera actively collaborates with healthcare professionals and researchers to enhance its understanding and treatment of this condition, and it is committed to sharing study results and findings with the broader medical community.